Talphera, Inc.
Talphera, Inc. (Nasdaq: TLPH) is a specialty pharmaceutical company focused on developing and commercializing therapies for medically supervised settings. Its portfolio centers on Niyad, a lyophilized nafamostat formulation being studied as a regional anticoagulant infused into the extracorporeal circuit during… From the company’s description.
In fiscal 2025, Talphera, Inc. reported revenue of $0.03M and a net loss of $14.29M. Operations used $11.36M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Talphera, Inc. does
In the company’s own words
Talphera, Inc. (Nasdaq: TLPH) is a specialty pharmaceutical company focused on developing and commercializing therapies for medically supervised settings. Its portfolio centers on Niyad, a lyophilized nafamostat formulation being studied as a regional anticoagulant infused into the extracorporeal circuit during continuous renal replacement therapy for hospitalized adults with acute kidney injury, particularly patients who cannot tolerate heparin or are at risk of bleeding. Niyad is in an ongoing U.S. registrational trial and has FDA Breakthrough Device Designation and an Investigational Device Exemption. The company is also evaluating LTX-608, a nafamostat formulation for direct intravenous infusion, for potential use in disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis or antiviral treatment. Its pre-filled syringe candidates include Fedsyra, an ephedrine product, and phenylephrine; the company is assessing whether to discontinue these programs. Talphera acquired Niyad and LTX-608 through its 2022 acquisition of Lowell Therapeutics. It divested DSUVIA in 2023 and no longer plans to develop other sufentanil products.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN MATEO, CA
- Fiscal year end
- December
- CIK
- 1427925
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Talphera, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Talphera, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Talphera, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Talphera, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Talphera, Inc.'s last four quarterly filings that the numbers alone won't show?”